Monitor for any actual share sales under this ATM program, which could lead to stock dilution. The mere availability of this capital raises the company's financial flexibility, but actual sales would be dilutive.
Price Chart
Executive Summary
Aardvark Therapeutics entered into an equity distribution agreement with Piper Sandler & Co. to potentially sell up to $150 million in common stock through an at-the-market offering. The company has no obligation to sell any shares and will pay a 3% commission on any sales.
Key Financial Metrics
Key Facts
- Aardvark Therapeutics entered into an equity distribution agreement with Piper Sandler & Co. on March 23, 2026
- The agreement allows for the potential sale of up to $150,000,000 in common stock through an at-the-market offering
- The company has no obligation to sell any shares under the agreement
- Piper Sandler will receive a 3.0% commission on the gross sales price of any shares sold
- Sales would be made pursuant to a shelf registration statement on Form S-3 (No. 333-294537)
Financial Impact
Up to $150 million in potential equity issuance with 3% commission paid to agent
Risk Factors
- Potential stock dilution if shares are sold under the program
- Downward pressure on stock price if significant sales occur
- Use of proceeds not specified, creating uncertainty about capital allocation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-120164 |
| Document: 0001193125-26-120164-index-headers.html | 0001193125-26-120164 |
| Document: 0001193125-26-120164-index.html | 0001193125-26-120164 |
| Document: 0001193125-26-120164.txt | 0001193125-26-120164 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | 8-K | $3.00 | awaiting T+1 | — | $1.39 (−53.67%) |
Oct 22, 2026 3d ago | 8-K | $3.95 | awaiting T+1 | — | $1.39 (−64.81%) |
Oct 22, 2026 3d ago | Press Release | $3.95 | awaiting T+1 | — | $1.39 (−64.81%) |
Oct 8, 2026 17d ago | 3 | $4.76 $4.45 | ▼ −6.51% | ▼ −6.45% | $1.39 (−70.80%) |
Oct 8, 2026 17d ago | 8-K | $4.76 $4.45 | ▼ −6.51% | ▼ −6.45% | $1.39 (−70.80%) |
Aug 12, 2026 10w ago | Institutional Cluster | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.39 (+78.84%) |
Aug 11, 2026 10w ago | 8-K | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.39 (+78.84%) |
Aug 11, 2026 10w ago | Press Release | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.39 (+78.84%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.64 $3.90 | ▲ +7.14% | ▲ +6.60% | $1.39 (−61.81%) |
May 14, 2026 23w ago | Press Release | $4.57 $4.36 | ▲ +4.60% | ▲ +4.53% | $1.39 (+69.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers